|1.||Taniguchi, Masaru: 20 articles (06/2009 - 03/2002)|
|2.||Van Kaer, Luc: 18 articles (02/2009 - 03/2002)|
|3.||Smyth, Mark J: 14 articles (01/2013 - 02/2002)|
|4.||Koezuka, Y: 12 articles (10/2001 - 01/2000)|
|5.||Nakayama, Toshinori: 11 articles (06/2009 - 03/2002)|
|6.||Kang, Chang-Yuil: 11 articles (02/2009 - 12/2004)|
|7.||Taniguchi, M: 8 articles (05/2008 - 01/2000)|
|8.||Godfrey, Dale I: 8 articles (02/2008 - 02/2002)|
|9.||Miyake, Sachiko: 8 articles (01/2008 - 01/2004)|
|10.||Yamamura, Takashi: 8 articles (01/2008 - 01/2004)|
12/01/2003 - "In addition, treatment of mice with alpha-GalCer significantly improved the outcome of this infection. "
11/01/2001 - "Finally, the enhanced production of IFN-gamma in IL-18KO mice correlated with increased host defense against cryptococcal infection, as indicated by enhancement in alpha-GalCer-related clearance of microorganisms. "
04/15/2014 - "When iNKT cells are activated, whether by alpha-galactosylceramide or during IAV infection, iNKT cells induced apoptosis of monocytes via a 4-1BB/L-independent mechanism, reducing monocyte numbers. "
09/15/2010 - "Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection."
06/01/2010 - "Although amelioration of infection by alpha-GalCer involves invariant natural killer T (iNKT)-cell activation, it remains to be determined whether macrophages (Mphi) participate in the control of microbial pathogens. "
09/01/2009 - "A combination of alpha-GalCer and AdmIL-2 (alpha-GalCer/AdmIL-2) inhibited the in vivo tumor growth and improved the survival of tumor-bearing mice, as compared to the use of a single agent. "
03/01/2007 - "In this study, we evaluated the capacity of non-DCs to present alpha-GalCer in vitro and in vivo, particularly tumor cells loaded with alpha-GalCer (tumor/Gal). "
10/01/2005 - "This drug potentially induces anti-tumor effect of NKT cells, and clinical trials for alpha-GalCer in cancer patients are ongoing in the world. "
01/01/2005 - "Although alpha-GalCer treatment of mice is associated with unwanted side-effects, it has been proven safe in clinical trials with cancer patients. "
08/10/2003 - "In conclusion, our study demonstrates clear differences in NK cell activation and anti-tumor effect through stimulation of NKT cells by alpha-GalCer between the liver and extrahepatic tissues. "
|3.||Autoimmune Diseases (Autoimmune Disease)
01/01/2005 - "As I discuss here, although preclinical studies have shown considerable promise for the development of treatment with alpha-GalCer as a therapeutic modality for autoimmune diseases, several obstacles need to be overcome before moving alpha-GalCer therapy from the bench to the bedside."
01/01/2008 - "As alpha-GalCer is the most efficacious ligand for iNKT cells, its potential to treat autoimmune disease has been evaluated in animal models. "
01/01/2005 - "alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles."
10/01/2002 - "Administration of alpha-GalCer-pulsed DCs is well tolerated, modulates PB Valpha24+ Vbeta11+ NKT cells and may have a role in the therapy of malignancies sensitive to activities of Valpha24+ Vbeta11+ NKT cells, or for autoimmune diseases."
05/01/2001 - "These findings strongly suggest that patients with autoimmune diseases can be divided into two groups (alpha-GalCer responders and nonresponders). "
|4.||Melanoma (Melanoma, Malignant)
04/01/2009 - "Loading ES-DC with alpha-galactosylceramide further enhanced the anticancer effects, suggesting that excellent synergic effects of TAA-specific cytotoxic T lymphocytes and natural killer T cells against metastatic melanoma can be achieved by using genetically modified ES-DC. "
12/01/2005 - "The ES-DC were loaded with alpha-GalCer and transferred to mice bearing MO4, an OVA-expressing melanoma, and their capacity to evoke antitumor immunity was evaluated. "
09/01/2001 - "These in vitro results show that Valpha24+NKT-cells stimulated by alpha-GalCer-pulsed Mo-DCs have anti-tumour activities against human melanoma through antiproliferative effects exerted by soluble mediators rather than cytolytic effects as observed against some other tumours. "
09/01/2001 - "Culture supernatants of activated Valpha24+NKT-cell cultures stimulated with alpha-GalCer pulsed Mo-DCs exhibited similar antiproliferative activities against melanoma cells, indicating that the majority of the inhibitory effects were due to soluble mediators rather than direct cell-to-cell interactions. "
09/01/2001 - "To investigate this, Valpha24+NKT-cells were generated from the peripheral blood of patients with melanoma after stimulation with alpha-GalCer pulsed monocyte-derived dendritic cells (Mo-DCs). "
|5.||Neoplasm Metastasis (Metastasis)
01/01/2010 - "In a murine mammary tumour model, we demonstrated that administration of either alpha-GalCer or anti-CD25 antibody alone markedly suppressed tumour formation and pulmonary metastasis, and resulted in an increase in the survival rate up to 44% (from a baseline of 0%). "
09/01/2009 - "Experiments on spontaneous metastasis models revealed that alpha-GalCer/AdmIL-2 reduced lung metastasis and prolonged survival, as compared to control groups. "
05/15/2007 - "The suppression by alpha-GalCer of experimental lung metastasis was markedly attenuated in SHPS-1 mutant mice compared with that apparent in wild-type (WT) mice. "
06/20/2005 - "In a series of experimental and spontaneous metastases models in mice, we demonstrate far superior antitumor activity of the alpha-GalCer/IL-21 combination above either agent alone. "
08/01/1999 - "Lymph node metastasis of B16-BL6-HM was almost completely blocked by alpha-GalCer treatment. "
|2.||Interleukin-12 (IL 12)
|10.||Interferon-gamma (Interferon, gamma)
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)